NATCO Pharma Q3 results: Key reasons that cause decline
Pharmaceutical company NATCO Pharma posted its results for the third quarter of fiscal 2024-25 (Q3 2025) on Wednesday.
The company reported a 37.75% year-on-year (YoY) decline causing a drop of 19% in its shares on Thursday.
The net profit dropped to ₹132.4 crore in the Q3 2025 compared to ₹212.7 crore in the previous quarter of last year.
The company’s consolidated revenue from operations declined by 37.4% to ₹474.8 crore in the third quarter from ₹758.6 crore last year.
The company’s consolidated revenue from operations declined by 37.4% to ₹474.8 crore in the third quarter from ₹758.6 crore last year.
Share price
The shares of NATCO Pharma slide 18.95% to ₹986 per share on the Bombay Stock Exchange (BSE).
At the time of closing the share dipped to the price of ₹975.05 apiece.
The key reasons include the decline in export formulation business which is the biggest revenue contributor for the company.
Reasons Behind Revenue Dip
The export formulation revenue declined to ₹285.8 crore from ₹605.6 crore in the third quarter last year.
Read full story here